Text/Editor: Dream Pen,

Yang Xiaoming, who once led the team to develop and market the world's first inactivated new crown vaccine, has now been dismissed. The news has sparked widespread attention, especially considering that he personally "tested the drug" and received the vaccine developed by his own team. He reportedly underwent about 60 blood tests over a nine-month period, which showed that he did not show any abnormalities after vaccination, with only a mild reaction to vaccination.

Is there more inside story behind the departure of this leading figure?

Watch the video first:

Loading...

Video source: Manager

Yang Xiaoming has not only made significant contributions to the field of COVID vaccines, but he is also an expert in infectious disease vaccine innovation. He led the team to successfully develop and market a variety of vaccines, including inactivated poliovirus vaccine and acellular diphtheria-pertussis combination vaccine. However, the recall has triggered a rethinking of his past achievements.

Under Yang Xiaoming's leadership, the speed of development of inactivated vaccines is miraculous. It took only more than 330 days from project approval to R&D and marketing, which is a leap compared with the previous traditional vaccine R&D cycle. This may be one of the reasons for his dismissal, and whether there was some kind of misconduct in the development of the vaccine will be the focus of attention.

The Hidden Truth Behind the Recall

Some reports have pointed out that Yang Xiaoming's resignation may be related to his suspected serious violations of discipline and law. The accusation calls into question his past research and reveals loopholes in the regulation of the vaccine industry. Against the backdrop of the pandemic, there is a greater focus on vaccine safety and transparency.

In addition to personal reasons, Yang's departure may also affect the future development of China Biotech and the entire vaccine industry. As a leading biopharmaceutical company, Sinobio has an important position in the field of vaccines. Whether Yang Xiaoming's departure will have an impact on the company's R&D plans and strategies will be the focus of attention of the market and investors.

In addition, the incident has sparked a deeper discussion about the inner workings and safety of the vaccine industry. Vaccine research and development is a complex and arduous task that requires strict regulation and transparent disclosure. Yang's recall could prompt regulators to tighten oversight of the vaccine industry to ensure public safety and trust.

The above is for reference only, Yang Xiaoming's recall incident not only raised everyone's concerns about vaccine health, but also reminded us that vaccine research and development need more strict supervision and transparent information disclosure. Only in this way can the health and safety of the public be guaranteed!

Is there a deeper reason behind this recall?

Note: The content of this article comes from the Internet, if it is inconsistent with the actual situation or there is infringement, please contact to delete

#杨晓明被罢免全国人大代表职务##杨晓明##国药集团原总工程师杨晓明被调查#